1330766-08-9 Usage
General Description
3-Boc-8-hydroxy-3-azabicyclo[3.2.1]octane is a complex organic chemical compound that contains the azabicyclo octane ring structure. This group of compounds is of significant interest in organic chemistry due to their distinctive stereochemistry. The compound is also notable for its Boc group, which signifies the presence of a t-butoxycarbonyl group, a common protecting group in organic synthesis. The hydroxy functional group in the compound may implicate it in chemical reactions characterized by the donation of protons or electrons. As such, 3-Boc-8-hydroxy-3-azabicyclo[3.2.1]octane could have potential application in the synthesis of a wide range of other chemicals, including potential pharmaceutical compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 1330766-08-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,3,0,7,6 and 6 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1330766-08:
(9*1)+(8*3)+(7*3)+(6*0)+(5*7)+(4*6)+(3*6)+(2*0)+(1*8)=139
139 % 10 = 9
So 1330766-08-9 is a valid CAS Registry Number.
1330766-08-9Relevant articles and documents
FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF
-
Paragraph 0072; 0075, (2018/11/27)
The present disclosure disclosed a modulator of FXR receptor and preparation and use thereof, which relates to the technical filed of medicinal chemistry. The present disclosure provides a modulator of FXR receptor having a structural formula I or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, which can combine with FXR receptor (that is NR1H4) and be acted as a FXR agonist or a partial agonist for preventing and treating the disease mediated by FXR, such as chronic intrahepatic or extrahepatic cholestasis, hepatic fibrosis caused by chronic cholestasis or acute intrahepatic cholestasis, chronic hepatitis B, gallstone, hepatic carcinoma, colon cancer or intestinal inflammatory disease, etc. Specifically, for some chemical compounds, their EC50 for FXR agonist activity reach below 100nM, which show an excellent FXR agonist activity and an excellent prospect to provide a new pharmaceutical selection in clinical treatment for the disease mediated by FXR.
